Cargando…
Country versus pharmaceutical company interests for hepatitis C treatment
Hepatitis C virus (HCV) is one of the leading causes of liver disease and is responsible for massive health and economic burden worldwide. The disease is asymptomatic in its early stages, but it can progress over time to fatal end-stage liver disease. Thus, the majority of individuals infected with...
Autores principales: | Lothan, Roy, Gutman, Noa, Yamin, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399601/ https://www.ncbi.nlm.nih.gov/pubmed/36001218 http://dx.doi.org/10.1007/s10729-022-09607-2 |
Ejemplares similares
-
Co-similar malware infection patterns as a predictor of future risk
por: Yavneh, Amir, et al.
Publicado: (2021) -
Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011) -
The influence of pharmaceutical companies
por: Migone, Paolo
Publicado: (2017) -
Pharmacovigilance in pharmaceutical companies: An overview
por: Mammì, Maria, et al.
Publicado: (2013) -
Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)